Form 4: Baker Bros. Advisors Report Changes in Beneficial Ownership of Incyte Corp (INCY)

Baker Bros. Advisors and related entities report changes in their beneficial ownership of Incyte Corp stock, including acquisitions of common stock in lieu of director fees.

Summary

• Baker Bros. Advisors LP and related entities, including Julian C. Baker and Felix J. Baker, filed a Form 4 detailing changes in their beneficial ownership of Incyte Corp (INCY) common stock.
• On June 28, 2024, Julian C. Baker acquired 537 shares of Incyte common stock in lieu of quarterly director retainer fees of $32,000.
• These shares are fully vested.
• The report also details the indirect beneficial ownership of common stock held by various Baker Bros. entities, including 667, L.P. and Baker Brothers Life Sciences, L.P.
• Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in these shares due to their roles within the Baker Bros. organization.
• The Adviser, Baker Bros. Advisors LP, has complete discretion over the investment and voting power of the securities held by the Funds.
• Julian C. Baker directly holds 278,773 shares of common stock, while Felix J. Baker directly holds 281,190 shares.
• Additionally, they may be deemed to have an indirect pecuniary interest in 33,410 shares held by FBB Associates.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. The acquisition of shares in lieu of fees could be seen as a slightly positive signal.

Positives

• Julian C. Baker's acquisition of shares in lieu of director fees demonstrates continued alignment with shareholder interests.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership by a major shareholder and board member, which is common in the biopharmaceutical industry.

Key Dates